Business

Mass. Movers

FDA report lifts Aegerion drug

istockphoto.com

Advertisement

Aegerion Pharmaceuticals Inc. shares jumped Monday after Food and Drug Administration medical reviewers said the Cambridge firm’s proposed drug to treat a rare genetic disorder that causes high cholesterol is effective at reducing it, but there is a potential to cause liver damage. The drug, lomitapide, will be reviewed on Wednesday by a panel of non-FDA medical specialists, which will make recommendations to the agency about whether lomitapide should be approved.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.